Wall Street analysts predict that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will post sales of $916.39 million for the current fiscal quarter, according to Zacks. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings. The highest sales estimate is $936.00 million and the lowest is $895.44 million. Alexion Pharmaceuticals posted sales of $870.00 million in the same quarter last year, which suggests a positive year-over-year growth rate of 5.3%. The business is scheduled to report its next quarterly earnings results on Thursday, April 26th.
According to Zacks, analysts expect that Alexion Pharmaceuticals will report full year sales of $916.39 million for the current financial year, with estimates ranging from $3.91 billion to $4.28 billion. For the next fiscal year, analysts forecast that the company will post sales of $4.69 billion per share, with estimates ranging from $4.34 billion to $4.89 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The company had revenue of $909.70 million during the quarter, compared to analyst estimates of $880.38 million. During the same quarter last year, the company earned $1.26 EPS. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis.
ALXN stock opened at $111.29 on Tuesday. Alexion Pharmaceuticals has a twelve month low of $96.18 and a twelve month high of $149.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. The company has a market cap of $24,635.08, a P/E ratio of 21.57, a P/E/G ratio of 1.04 and a beta of 1.13.
In other Alexion Pharmaceuticals news, EVP John B. Moriarty sold 1,261 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $117.26, for a total transaction of $147,864.86. Following the sale, the executive vice president now directly owns 20,210 shares in the company, valued at approximately $2,369,824.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP John B. Moriarty sold 3,363 shares of the stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $115.70, for a total value of $389,099.10. Following the sale, the executive vice president now owns 71,400 shares in the company, valued at $8,260,980. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,700 shares of company stock worth $3,345,708. Company insiders own 4.35% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Factory Mutual Insurance Co. boosted its stake in shares of Alexion Pharmaceuticals by 104.5% in the 4th quarter. Factory Mutual Insurance Co. now owns 358,500 shares of the biopharmaceutical company’s stock worth $42,873,000 after buying an additional 183,200 shares during the last quarter. Creative Planning boosted its stake in shares of Alexion Pharmaceuticals by 72.2% in the 4th quarter. Creative Planning now owns 27,773 shares of the biopharmaceutical company’s stock worth $3,321,000 after buying an additional 11,642 shares during the last quarter. Boston Advisors LLC boosted its stake in shares of Alexion Pharmaceuticals by 3.0% in the 4th quarter. Boston Advisors LLC now owns 149,241 shares of the biopharmaceutical company’s stock worth $17,848,000 after buying an additional 4,315 shares during the last quarter. Twin Capital Management Inc. boosted its stake in shares of Alexion Pharmaceuticals by 26.5% in the 4th quarter. Twin Capital Management Inc. now owns 38,786 shares of the biopharmaceutical company’s stock worth $4,638,000 after buying an additional 8,136 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Alexion Pharmaceuticals by 3.9% in the 4th quarter. Rhumbline Advisers now owns 403,489 shares of the biopharmaceutical company’s stock worth $48,253,000 after buying an additional 15,174 shares during the last quarter. Hedge funds and other institutional investors own 95.07% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://dakotafinancialnews.com/2018/04/13/alexion-pharmaceuticals-inc-alxn-expected-to-post-quarterly-sales-of-916-39-million.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.